New hope for UC patients: early biologic therapy may outperform standard care
NCT ID NCT07235904
First seen Nov 19, 2025 · Last updated Apr 24, 2026 · Updated 21 times
Summary
This study compares early treatment with mirikizumab (a biologic) to the standard approach with azathioprine in 300 adults newly diagnosed with moderate-to-severe ulcerative colitis. Participants are randomly assigned to receive either mirikizumab or azathioprine for 52 weeks. The goal is to see if starting with mirikizumab leads to better disease control, including remission without steroids, improved quality of life, and fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospital Schleswig-Holstein
RECRUITINGKiel, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.